-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Lung cancer is the most common cause of cancer-related death among the world, including two types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
previous studies have shown that PPAR gamma (peroxidase proliferative activated by the ligand) astrogen induces the death of non-small cell lung cancer (NSCLC) cells.
, however, most NSCLC patients develop drug resistance after treatment, and the molecular mechanisms are not yet known.
study aims to explore the apoptosis mechanism and anti-cancer effect of the new PPAR astrogen CB11, as well as the effects on NSCLC cells.
researchers found that in human NSCLC cells, CB11 activates the ROS-mediated ATM-p53-GADD45 alpha signaling path path, which in turn causes cell death reactions, while THEPIs inhibitor DPI inhibites the ATM signaling path of CB11 and reduces cell death.
of CB11 in CB11 showed that CB11 significantly reduced tumor volume compared to the control group.
addition, for NSCLC cells with radiotherapy resistance, CB11 inhibits the occurrence of cell death induced by the endosthorption-interstitial transformation (EMT) process.
, however, the absence of PPAR gamma inhibits cell death by blocking the activation of radiation/CB11-induced ATM-p53 pathlines.
results show that the new PPAR astrogen CB11 may become a new type of anti-cancer drug, and has a certain contribution to the treatment of radiation resistance of non-small cell lung cancer.
.
